{"id":"prednisolone-mabthera","safety":{"commonSideEffects":[{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Prednisolone works by inhibiting the production of inflammatory cytokines, thereby reducing inflammation and immune response. Mabthera, on the other hand, binds to CD20 on B cells, marking them for destruction and reducing B cell-mediated immune responses.","oneSentence":"Prednisolone is a corticosteroid that suppresses the immune system, while Mabthera (rituximab) is a monoclonal antibody that targets CD20 on B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:56.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin's lymphoma"},{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT01679119","phase":"PHASE2","title":"Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":129},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT05800366","phase":"PHASE2","title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-04-06","conditions":"Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":41},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT03286556","phase":"PHASE2","title":"Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-04","conditions":"Idiopathic Pulmonary Fibrosis, Acute Fatal Form","enrollment":82},{"nctId":"NCT04980222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-22","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT03384277","phase":"PHASE4","title":"Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2017-12-29","conditions":"Acquired Hemophilia A","enrollment":66},{"nctId":"NCT06097364","phase":"PHASE3","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-11-14","conditions":"Follicular Lymphoma (FL)","enrollment":733},{"nctId":"NCT06091865","phase":"PHASE3","title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-13","conditions":"Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":904},{"nctId":"NCT04884035","phase":"PHASE1","title":"Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","status":"RECRUITING","sponsor":"Celgene","startDate":"2021-09-15","conditions":"Lymphoma, B-Cell","enrollment":174},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT07233330","phase":"PHASE2","title":"Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2026-02","conditions":"Nephrotic Syndrome，Idiopathic","enrollment":10},{"nctId":"NCT06970743","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-05-29","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":150},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":324},{"nctId":"NCT05468320","phase":"PHASE3","title":"Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-11-21","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":51},{"nctId":"NCT04661007","phase":"PHASE1, PHASE2","title":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Biosciences Japan GK","startDate":"2020-12-15","conditions":"Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma","enrollment":72},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT03952637","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2019-08-19","conditions":"Lysosomal Diseases, Gangliosidosis, GM1","enrollment":54},{"nctId":"NCT04540380","phase":"PHASE1","title":"Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-09-01","conditions":"Renal Failure","enrollment":20},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":"Follicular Lymphoma","enrollment":400},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT05136976","phase":"PHASE3","title":"Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-06-29","conditions":"Anti-MAG Neuropathy","enrollment":90},{"nctId":"NCT02433522","phase":"PHASE3","title":"Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-03-31","conditions":"ANCA-associated Vasculitides","enrollment":97},{"nctId":"NCT01748084","phase":"PHASE2, PHASE3","title":"Rituximab in Systemic Sclerosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-04-09","conditions":"Systemic Sclerosis","enrollment":22},{"nctId":"NCT04981912","phase":"PHASE1","title":"Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2021-09-02","conditions":"Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","enrollment":4},{"nctId":"NCT07049172","phase":"NA","title":"Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome","status":"COMPLETED","sponsor":"Wuhan Children's Hospital","startDate":"2021-01-01","conditions":"Nephrotic Syndrome in Children","enrollment":91},{"nctId":"NCT04479267","phase":"PHASE2","title":"Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2020-08-21","conditions":"Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements","enrollment":8},{"nctId":"NCT04074187","phase":"PHASE2, PHASE3","title":"A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-21","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":21},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":899},{"nctId":"NCT01810588","phase":"PHASE2","title":"Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2012-10-16","conditions":"Hematologic Malignancies","enrollment":270},{"nctId":"NCT07124936","phase":"PHASE1, PHASE2","title":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-07-30","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":97},{"nctId":"NCT04546620","phase":"PHASE2","title":"Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2021-10-19","conditions":"Diffuse Large B Cell Lymphoma","enrollment":453},{"nctId":"NCT04688788","phase":"PHASE3","title":"Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-04-28","conditions":"Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":600},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT00945724","phase":"PHASE2","title":"Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-09-27","conditions":"Large B-cell Diffuse Lymphoma of Testis","enrollment":54},{"nctId":"NCT06594640","phase":"PHASE1, PHASE2","title":"R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-30","conditions":"Diffuse Large B-cell Lymphoma","enrollment":108},{"nctId":"NCT00550342","phase":"PHASE2","title":"Rituximab Treatment of Focal Segmental Glomerulosclerosis","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2008-01","conditions":"Focal Segmental Glomerulosclerosis (FSGS)","enrollment":""},{"nctId":"NCT06611696","phase":"PHASE4","title":"Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis","status":"RECRUITING","sponsor":"Chiba University","startDate":"2024-11-15","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":160},{"nctId":"NCT01303887","phase":"PHASE3","title":"A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2009-10","conditions":"Follicular Lymphoma","enrollment":680},{"nctId":"NCT03994783","phase":"PHASE3","title":"Transplant Antibody-Mediated Rejection: Guiding Effective Treatments","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2019-07-17","conditions":"Kidney Transplant Rejection, Antibody-mediated Rejection","enrollment":3},{"nctId":"NCT05545384","phase":"PHASE3","title":"Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-04","conditions":"Acute Demyelinating Syndrome","enrollment":86},{"nctId":"NCT05303792","phase":"PHASE2","title":"Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-06-09","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma","enrollment":68},{"nctId":"NCT03194815","phase":"PHASE2","title":"IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2017-11-01","conditions":"Psychosis, Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT02378298","phase":"PHASE4","title":"Rituximab (RTX) Therapy in Patients With Active TAO","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2011-12","conditions":"Ophthalmopathy, Thyroid-Associated","enrollment":38},{"nctId":"NCT03206671","phase":"PHASE3","title":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Muenster","startDate":"2017-08-03","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":650},{"nctId":"NCT06871007","phase":"PHASE1, PHASE2","title":"Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma","status":"ENROLLING_BY_INVITATION","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2024-09-01","conditions":"Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children, Nivolumab","enrollment":22},{"nctId":"NCT05850546","phase":"PHASE3","title":"Rituximab in the First Episode of Paediatric Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-03-01","conditions":"Steroid-Sensitive Nephrotic Syndrome","enrollment":138},{"nctId":"NCT02626455","phase":"PHASE3","title":"Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-01-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":551},{"nctId":"NCT04323566","phase":"PHASE2","title":"Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement","status":"ENROLLING_BY_INVITATION","sponsor":"Uppsala University Hospital","startDate":"2022-05-01","conditions":"Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia","enrollment":40},{"nctId":"NCT06680349","phase":"PHASE4","title":"Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis","status":"COMPLETED","sponsor":"University of Turin, Italy","startDate":"2022-12-01","conditions":"Fibrillary Glomerulonephritis","enrollment":21},{"nctId":"NCT03747159","phase":"PHASE3","title":"Synergetic B-cell Immunomodulation in SLE - 2nd Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2018-10-01","conditions":"Lupus Erythematosus, Systemic","enrollment":70},{"nctId":"NCT05406401","phase":"PHASE2","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-14","conditions":"Lymphoma, Large B-Cell, Diffuse (DLBCL)","enrollment":60},{"nctId":"NCT02889523","phase":"PHASE1, PHASE2","title":"Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2016-10","conditions":"Lymphoma, DLBCL, Follicular Lymphoma","enrollment":214},{"nctId":"NCT00004112","phase":"PHASE3","title":"Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"1999-09-01","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT04914741","phase":"PHASE1, PHASE2","title":"A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2021-06-29","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma","enrollment":80},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT04933617","phase":"PHASE1","title":"Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-24","conditions":"Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma","enrollment":8},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT05679336","phase":"NA","title":"Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2018-05-01","conditions":"Membranous Nephropathy - PLA2R Induced","enrollment":40},{"nctId":"NCT05843968","phase":"PHASE2","title":"Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome","status":"RECRUITING","sponsor":"Children's Hospital of Chongqing Medical University","startDate":"2023-01-29","conditions":"Nephrotic Syndrome in Children","enrollment":46},{"nctId":"NCT05514015","phase":"PHASE4","title":"Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-03-29","conditions":"Primary Membranous Nephropathy","enrollment":78},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":"B Lymphoblastic Leukemia","enrollment":500},{"nctId":"NCT06245707","phase":"NA","title":"the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2023-10-01","conditions":"Mild Cognitive Impairment, Idiopathic Membranous Nephropathy","enrollment":2},{"nctId":"NCT04263584","phase":"PHASE2","title":"Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL","status":"UNKNOWN","sponsor":"University Hospital Muenster","startDate":"2020-06-19","conditions":"Diffuse Large B Cell Lymphoma","enrollment":62},{"nctId":"NCT03399513","phase":"PHASE2","title":"Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2018-05-03","conditions":"Diffuse Large B Cell Lymphoma","enrollment":40},{"nctId":"NCT06188676","phase":"PHASE3","title":"Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2022-04-01","conditions":"Primary Mediastinal Lymphoma","enrollment":100},{"nctId":"NCT03942887","phase":"PHASE3","title":"Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2019-05-03","conditions":"ANCA Associated Vasculitis","enrollment":100},{"nctId":"NCT06068829","phase":"","title":"Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders","status":"UNKNOWN","sponsor":"Feng Jinzhou","startDate":"2023-10-20","conditions":"Neuromyelitis Optica Spectrum Disorders","enrollment":80},{"nctId":"NCT03571308","phase":"PHASE1, PHASE2","title":"A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2017-06-02","conditions":"Non Hodgkin Lymphoma","enrollment":39},{"nctId":"NCT05820841","phase":"PHASE3","title":"Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2023-06-07","conditions":"Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":330},{"nctId":"NCT05734794","phase":"PHASE3","title":"Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2023-02-09","conditions":"Nephrotic Syndrome in Children, Rituximab","enrollment":80},{"nctId":"NCT05990985","phase":"NA","title":"The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.","status":"NOT_YET_RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2023-09-01","conditions":"Diffuse Large B-cell Lymphoma","enrollment":20},{"nctId":"NCT05969522","phase":"PHASE4","title":"Stratified Therapy on Pediatric AAGN","status":"UNKNOWN","sponsor":"Wang Mo","startDate":"2023-01-01","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, ANCA-Associated Glomerulonephritis","enrollment":200},{"nctId":"NCT05376709","phase":"NA","title":"A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2020-09-01","conditions":"Lymphoma, B-Cell","enrollment":200},{"nctId":"NCT05874778","phase":"PHASE2","title":"A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-05-15","conditions":"Advanced Diffuse Large B-Cell Lymphoma, Extra-nodal Involvement, Large Mass, Radiotherapy","enrollment":108},{"nctId":"NCT03003520","phase":"PHASE2","title":"A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-02-28","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":46},{"nctId":"NCT05861297","phase":"PHASE4","title":"Immune Thrombocytopenia Management in Adults","status":"UNKNOWN","sponsor":"Nahda University","startDate":"2020-05-05","conditions":"Immune Thrombocytopenia Purpura","enrollment":467},{"nctId":"NCT05824390","phase":"PHASE4","title":"A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy","status":"UNKNOWN","sponsor":"XIEJINGYUAN","startDate":"2020-06-20","conditions":"IgA Nephropathy","enrollment":116},{"nctId":"NCT05782933","phase":"NA","title":"Efficacy of Rituximab Combined With Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2022-08-04","conditions":"Idiopathic Membranous Nephropathy","enrollment":2},{"nctId":"NCT00198978","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-01","conditions":"Adult Acute Lymphocytic Leukemia","enrollment":377},{"nctId":"NCT01992653","phase":"PHASE1, PHASE2","title":"A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2013-11-29","conditions":"Lymphoma, Non Hodgkin","enrollment":85},{"nctId":"NCT01086540","phase":"PHASE2","title":"Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-06-24","conditions":"Systemic Sclerosis-Associated PAH","enrollment":57},{"nctId":"NCT03899337","phase":"PHASE2","title":"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-07-23","conditions":"Richter Syndrome","enrollment":105},{"nctId":"NCT04494438","phase":"PHASE3","title":"Rituximab for Idiopathic Nephrotic Syndrome","status":"COMPLETED","sponsor":"Istituto Giannina Gaslini","startDate":"2013-07","conditions":"Idiopathic Nephrotic Syndrome","enrollment":30},{"nctId":"NCT00379431","phase":"PHASE2","title":"A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2006-11-27","conditions":"Early and Severe Systemic Sclerosis","enrollment":9},{"nctId":"NCT00115700","phase":"PHASE3","title":"Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma","status":"COMPLETED","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2000-02","conditions":"Follicular Lymphoma","enrollment":150},{"nctId":"NCT01319981","phase":"PHASE2","title":"Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-03-05","conditions":"Leukemia","enrollment":31},{"nctId":"NCT05532111","phase":"NA","title":"Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-09-01","conditions":"Efficacy and Safety","enrollment":60},{"nctId":"NCT00199082","phase":"PHASE4","title":"Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults","status":"COMPLETED","sponsor":"Nicola Goekbuget","startDate":"2002-07","conditions":"Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Neoplasms","enrollment":650},{"nctId":"NCT01332968","phase":"PHASE3","title":"A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-06","conditions":"Non-Hodgkin's Lymphoma","enrollment":1401},{"nctId":"NCT01516593","phase":"PHASE2","title":"Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma","status":"COMPLETED","sponsor":"Andres J. M. Ferreri","startDate":"2011-11","conditions":"HIV, Burkitt's Lymphoma","enrollment":19},{"nctId":"NCT02115997","phase":"PHASE4","title":"A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-07-06","conditions":"Wegener's Granulomatosis or Microscopic Polyangiitis","enrollment":30},{"nctId":"NCT05280626","phase":"PHASE2","title":"First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-03-25","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":100},{"nctId":"NCT02293109","phase":"PHASE1","title":"Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Mehrdad Abedi, MD","startDate":"2015-12-17","conditions":"Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["mabthera equals Rituximab"],"phase":"phase_3","status":"active","brandName":"prednisolone + mabthera","genericName":"prednisolone + mabthera","companyName":"Copenhagen University Hospital at Herlev","companyId":"copenhagen-university-hospital-at-herlev","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisolone is a glucocorticoid receptor agonist, classified as a small molecule. It is used in combination with Mabthera (rituximab) to treat various conditions, including IgA Nephropathy, Rheumatoid Arthritis, Nephrotic Syndrome, Thrombotic Thrombocytopenic Purpura, and Primary Mediastinal (Thymic) Large B-cell Lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}